Introduction {#s1}
============

The thalamus plays a central role in altering and maintaining arousal ([@BHU220C61]; [@BHU220C71]). Anatomically, its nuclei are topographically organized to modulate and synchronize distributed cortical networks supporting large-scale cerebral dynamics related to goal-directed behaviors and awareness ([@BHU220C58]). On this basis, it was suggested that phenomenal consciousness is generated by synchronized neural activity in thalamic neurons and that thalamic activity is driven by information arising from the cortical computation ([@BHU220C71]).

Abnormal functional connectivity and microstructural damage within thalami have been previously reported in dementia with Lewy bodies (DLB) ([@BHU220C72]; [@BHU220C34]). DLB patients were clinically characterized by spontaneous alteration in cognition, attention, and arousal ([@BHU220C39]). These symptoms were reported as fluctuating cognition (flCog), which represents, together with visual hallucinations and extrapyramidal signs, the core clinical features of DLB ([@BHU220C44]).

Several neuroimaging studies have focused on the neural bases of flCog in DLB patients, suggesting a relation between the severity of flCog and covariant perfusional network changes ([@BHU220C63]) or functional magnetic resonance imaging (fMRI) blood oxygen-dependent level (BOLD) ([@BHU220C23]; [@BHU220C52]) alterations. In addition, increased thalamic perfusion on single photon emission computed tomography (SPECT) ([@BHU220C49]) and changes in dopaminergic and cholinergic systems within thalami have been linked to flCog in DLB ([@BHU220C56]; [@BHU220C55]). Of note, the cholinergic system is widely distributed in the brain and it is more affected in DLB than in Alzheimer\'s disease (AD) patients ([@BHU220C37]). This concept is amply supported by pharmacological evidences which suggest that (1) anticholinergic drugs can induce a symptom profile of altered arousal comparable to flCog in DLB ([@BHU220C54]) and (2) cholinesterase inhibitors can significantly improve flCog and attentional function in DLB ([@BHU220C43]; [@BHU220C50]; [@BHU220C73]).

Based on these considerations and on the central role of thalamic neurons in regulating arousal and attention, we hypothesized that cholinergic imbalance within thalami and damage of the structural connectivity between thalami and cortical regions modulating alertness and attention are associated with flCog in DLB.

To test this, we carried out a study using multimodal techniques including structural magnetic resonance imaging (MRI), diffusion tensor imaging (DTI) and proton MR Spectroscopy (^1^H-MRS) in a cohort of DLB and AD patients as well as healthy controls. ^1^H-MRS technique assesses, in vivo, different metabolites such as *N*-acetyl-aspartate (NAA) and total choline (tCho) which are specifically related to decrease of neuronal integrity and to cholinergic deficits respectively. The combination of structural MRI and DTI allows parcellation of the thalami according to their cortical structural connectivity and to investigate microstructural integrity in each connectivity-defined region. The comparison between DLB and AD was performed to assess whether any possible structural and metabolic changes in the thalami were specific of a dementia characterized by the presence of flCog (DLB) or more as a result of a process of dementia per se. Furthermore, the variation of severity and frequency of flCog among DLB patients provides a means by which to assess whether the MR thalamic changes are associated with more overt flCog.

Material and Methods {#s2}
====================

Study Sample {#s2a}
------------

This study was approved by Local Institutional Ethics Committee. All participants (or their caregivers) gave written informed consent. Sixteen AD and 16 DLB patients were recruited from our Memory Clinic and Movement Disorder Clinic. Thirteen age-matched volunteers come from our nondemented case register cohorts. The diagnosis of probable AD was made using National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer\'s Disease and Related Disorders Association criteria ([@BHU220C45]). The probable DLB diagnosis was based on consensus guidelines ([@BHU220C44]) with a specific restriction: we included only patients with the presence of flCog, plus at least one additional core feature (visual hallucination or parkinsonism) or the presence of flCog plus one or more suggestive features ([@BHU220C44]).

As part of their clinical work up within 6 months before the inclusion in the study, all patients underwent computerized tomography or MRI and dopaminergic presynaptic ligand ioflupane SPECT (DAT scan). In addition all patients were assessed with electroencephalography (EEG) recordings as abnormalities characterized by parieto-occipital dominant frequency alterations have previously been shown to reliably differentiate probable DLB from AD ([@BHU220C6]). DAT scans and EEG Compressed Spectral Array patterns (as defined in [@BHU220C6]), performed prior to entry into the study, were used to support the diagnosis of DLB.

Clinical Evaluation {#s2b}
-------------------

Mini mental state examination (MMSE), clinical dementia rating (CDR) and Dementia rating scale-2 (DRS-2) ([@BHU220C29]) were performed for global cognitive assessment. Frontal assessment battery (FAB) was performed to evaluate the severity of frontal dysfunction ([@BHU220C18]). The frequency and duration of flCog were assessed by CAF questionnaire ([@BHU220C70]); this is a well established tool and while it has been superseded by scales which may have better diagnostic utility in distinguishing flCog in DLB compared with AD (e.g., dementia cognitive fluctuation scale, [@BHU220C38]), the CAF remains validated as a measure of the severity and frequency of flCog and has been used in numerous studies as a metric to examine the pathophysiological basis of flCog ([@BHU220C3]; [@BHU220C4]; [@BHU220C6]; [@BHU220C63]; [@BHU220C52]). A CAF score between 2 and 16 was considered sufficient to define a patient as affected by flCog ([@BHU220C6]). Based on this criterion only a 2% of our DLB selected population was excluded from the study. AD patients were selected on the basis of having no clinical history of flCog (CAF score of zero). Extrapyramidal signs were assessed using the motor part of the Unified Parkinson\'s Disease Rating Scale (UPDRS) III ([@BHU220C19]). The Neuropsychiatric Inventory (NPI) scale was used to evaluate neuropsychiatric features ([@BHU220C12]). The NPI hallucinations item-2 scale was performed to investigate the occurrence and severity of visual hallucinations. Minimal International Classification of Sleep Disorders criteria were used to assess REM sleep behavior disorder (RBD) ([@BHU220C74]). Since ^1^H-MRS spectra are sensitive to pharmacological manipulations ([@BHU220C26]; [@BHU220C62]; [@BHU220C32]), pharmacological treatments were withdrawn on the day of MR session ([@BHU220C50]; [@BHU220C7]; [@BHU220C23]).

MR Protocol {#s2c}
-----------

All MR data were acquired with a Philips Achieva 3 T scanner (Philips Medical System, Best, the Netherlands) equipped with 8-channel receiver coil. Three-dimensional *T*~1~-weighted images were acquired by using Turbo Field-Echo sequence (TFE, TR/TE = 11/5 ms, slice thickness of 0.8 mm). Two ^1^H-MRS voxels of 1.5 × 1.0 × 1.5 mm^3^ were accurately placed on right and left thalami, respectively (Fig. [1](#BHU220F1){ref-type="fig"}*A*). Point-resolved spectroscopy sequences (TR/TE = 2000/39 ms, 16-step phase-cycle and an average of 128 scan) with and without water suppression were performed by using chemically shift selective (CHESS) pulses. One thousand and twenty-four points were acquired with a spectral width of 2000 Hz. *T*~2~-weighted fluid attenuation inversion recovery sequence \[FLAIR, time repetition (TR)/time echo (TE) = 11 000/125 ms, slice thickness of 4 mm, field of view (FOV) = 240 × 129 × 222 mm\] was performed to exclude participants with concomitant vascular pathology or with white matter abnormalities outside the normal range. Figure 1.Proton magnetic resonance spectroscopy (^1^H-MRS). (*A*) Two voxels of 1.5 × 1.0 × 1.5 mm^3^ were, respectively, placed on right and left thalami by using *T*~1~-weighted image as anatomical reference. (*B*) Representative spectra for DLB, AD, and controls. Estimated signals (violet) were reported on original signals (red). NAA, *N*-acetyl-aspartate (2.02 ppm); tCr, total creatine (3.03 ppm); tCho, total choline (3.22 ppm). (*C*) Scatterplot expresses the linear regression between CAF scores and tCho/tCr values in the right thalamus. AD, Alzheimer\'s disease; DLB, dementia with Lewy bodies. Values marked with an asterisk are overlapped.

^1^H-MRS Analysis {#s2d}
-----------------

^1^H-MRS data analysis was performed by using JMRUI version 4.0 ([@BHU220C48]). Spectra with water suppression were filtered for removal of residual water by using the Hankel Lanczos Singular Values Decomposition algorithm. After autophasing, baseline and frequency shifts correction, a priori knowledge database (NAA, 2.02 ppm; total creatine = tCr, 3.03 ppm; tCho, 3.22 ppm) was created to put constraints on the advanced magnetic resonance fitting algorithm within jMRUI package. Peak shifts were restricted to ±5 ppm of the theoretical location. Spectra with artifact and metabolites fits with Cramer Rao Lower Bounds \>20% were excluded.

For applicability to the clinical practice and because several ^1^H-MRS studies report stable tCr levels in dementias ([@BHU220C67]; [@BHU220C13]; [@BHU220C9]; [@BHU220C30]), we expressed NAA and tCho relatively to tCr. By using spectra without water suppression, we calculated the area of the water peak and we used it as an internal reference standard for absolute tCr quantification ([@BHU220C10]; [@BHU220C14], [@BHU220C15]).

Parcellation of Thalami {#s2e}
-----------------------

Functional MRI of the Brain (FMRIB) Software Library (FSL, version 5.0; <http://www.fmrib.ox.ac.uk/fsl>, [@BHU220C60]) was used to perform structural connectivity-based parcellation of thalami and to investigate microstructural changes in each thalamic region. For each subject, mean diffusivity (MD) maps were generated from a tensor-model fit in FSL (FDT, FMRIB\'s Diffusion Toolbox). Thalami parcellation was performed according to methods described by [@BHU220C5]. Four cortical masks including prefrontal, sensorimotor, temporal, and parieto-occipital regions were defined using the Harvard Oxford Cortical Atlas (implemented in FSL) (Fig. [2](#BHU220F2){ref-type="fig"}*A*). The composition of each target region was reported in [Supplementary Table 1](http://cercor.oxfordjournals.org/lookup/suppl/doi:10.1093/cercor/bhu220/-/DC1). FMRIB\'s Integrated Registration and Segmentation Tool (FIRST) was used to automatically segment thalami ([@BHU220C78]) and its outputs were binarized to obtain masks. All cortical and subcortical masks were in MNI space (1 × 1 × 1 mm). After Bayesian estimation of diffusion parameters obtained using sampling techniques, the DTI maps were registered to MNI standard space using: (1) FLIRT to register each subject\'s b0 image to its native structural image, and (2) FMRIB\'s nonlinear registration tools to register the structural and diffusion images to MNI space (1 × 1 × 1 mm). All masks were then propagated onto each individual\'s DTI scalar maps using the inverse of the above transformations. To exclude thalamic voxels that contained cerebrospinal fluid (CSF), the b0 images were segmented using FMRIB\'s Automated Segmentation Tool (FAST) and CSF binarized to be used as exclusion mask. To exclude voxels out of the thalamic range, manual editing was applied where needed. Next, probabilistic tracking was carried out by probabilistic tracking (PROBTRACKX) tool. "Find the biggest" command line was used to define the thalamic connectivity-defined subregions according to their highest probability of connection with cortical regions (Fig. [2](#BHU220F2){ref-type="fig"}*B*). Two experienced operators visually inspected the "find the biggest" outputs, verifying the anatomic correspondence of each thalamic connectivity-defined subregion among subjects and their accordance with Oxford Thalamic Connectivity Atlas (integrated in FSL, [@BHU220C77]; Fig. [2](#BHU220F2){ref-type="fig"}*C*). Figure 2.Structural connectivity. (*A*) Cortical rendering of target regions used for thalami parcellation (colors were in agreement with thalamic connectivity). (*B*) Connectivity-based subdivision of thalami for controls (CON), dementia with Lewy bodies (DLB), and Alzheimer\'s disease (AD). Thalamic voxels are classified and colored according to the highest probability of connection to specific cortical regions. Red, connectivity-defined subregion (CDR) that projects from thalamus to prefrontal cortex; blue, CDR that projects from thalamus to sensorimotor cortex; yellow, CDR that projects from thalamus to parieto-occipital cortex; green, CDR that projects from thalamus to temporal cortex. (*C*) Thalami regions defined by Oxford Thalamic Connectivity Atlas. (*D*) Within-group probabilistic tractography maps for each cortical target region. The significant results are shown by voxels rating from red to yellow (*P* \< 0.05, FWE-corrected). No significant differences were found among groups. PFC, prefrontal; SM, sensorimotor; PO, parieto-occipital; TMP, temporal.

Finally, MD values were calculated in each connectivity-defined subregion.

Given that some cortical regions in DLB and/or AD could be characterized by changes in regional cerebral blood flow ([@BHU220C11]) and the diffusion indices could be biased by different location and volume of thalamic connectivity-defined regions determined by the tracking algorithm, we adopted 3 different strategies. Firstly, we verified whether the spatial distribution and the connection probability within each thalamic connectivity-defined region were altered by the pathological underlying condition ([@BHU220C47]). Specifically, by using "randomize" command line, we carried out comparisons within and between groups on the maps of connection probability generated by PROBTRACKX (Fig. [2](#BHU220F2){ref-type="fig"}*D*). Family-wise error (FEW) correction was applied to obtain the significant voxels. Secondly, we verified whether the volumes of each thalamic region defined by "find the biggest" were significantly different among groups. Specifically, for each subject, the volumes of thalamic regions were calculated by "fslstats" command line and, next, they were normalized for ipsilateral thalamic volume. Third, we verified whether the MD values in each thalamic region were related to differences found by tracking probability. Specifically, we defined the thalamic regions from Oxford thalamic connectivity atlas and we extracted MD values from them. Finally, we performed multivariate analysis of variance (MANOVA) on MD values to test whether the 2 methods (probabilistic parcellation and atlas) provided different results for thalamic regions.

Statistical Analysis {#s2f}
--------------------

Analysis of variance (ANOVA) among groups was carried out on demographic and clinical data. *χ*^2^ test was carried out for gender.

We performed multivariate analysis of covariance (MANCOVA) to exclude the possible effect of cognitive impairment on different imaging findings obtained from demented patients and controls. Next, MANOVA was carried out to test the differences among groups (AD, DLB, and controls). Tukey\'s HSD post hoc test was performed for assessing pair-wise differences between groups. For all comparisons, significance level was set at *P* \< 0.05.

Linear regression was performed to assess the relationship between MR outcomes in DLB patients (MD within right and left connectivity-defined subregions and metabolites/tCr within left and right thalami) and CAF scores (our primary clinical measure). Age, MMSE, NPI hallucination-item, UPDRS scores were included as nuisance factors. All results were corrected for multiple comparisons using Bonferroni\'s correction (*P* = 0.05/12 = 0.004).

Results {#s3}
=======

Demographic and Clinical Features {#s3a}
---------------------------------

Table [1](#BHU220TB1){ref-type="table"} summarizes demographic features and neuropsychological test scores. Groups did not differ for age, gender, and educational level. CAF scores ranged between 2 and 12 in DLB patients. All DLB patients showed an abnormal quantitative EEG pattern profile consistent with a DLB diagnosis ([@BHU220C6]) and represented by slow dominant frequency (in the theta and prealpha band) in posterior leads and a dominant frequency variability \>1.5 Hz. None of the AD patients or controls showed these DLB-specific EEG characteristics ([@BHU220C6]). No differences on global test of cognition and on severity of frontal dysfunction were reported between AD and DLB patients. Fourteen DLB patients had RBD. Dopamine-transporter hypocaptation in the caudate nuclei at SPECT-DAT scan was observed in all DLB patients, and it was bilateral in 12 patients. SPECT-DAT scan abnormalities were not observed in AD patients or control subjects. Table 1Demographic and clinical featuresCharacteristicsControlsADDLBNumber of subjects/patients131616Age^a,b^75.6 ± 4.775.5 ± 5.475.6 ± 4.2Male gender (%)^c^46%50%50%Disease duration (years)^d^--3.1 ± 0.73.0 ± 0.6Education level (years)^a,e^7 ± 47 ± 37 ± 4Clinical dementia rating^a,f^--2.3 ± 0.62.3 ± 0.7Mini mental state examination^a,g^28.3 ± 1.317.7 ± 4.517.9 ± 4.5Dementia rating scale^a,h^136.6 ± 0.791.4 ± 18.191.7 ± 15.8Frontal assessment battery^a,i^17.6 ± 0.58.4 ± 2.78.6 ± 2.7Clinician assessment of fluctuations0.0 ± 0.00.0 ± 0.04.9 ± 2.9Unified Parkinson\'s disease rating scale III0.0 ± 0.00.0 ± 0.025.8 ± 10.0Neuropsychiatric inventory-item 2 hallucinations0.0 ± 0.00.0 ± 0.04.0 ± 1.8[^1][^2][^3][^4][^5][^6][^7][^8][^9][^10]

The patients were on a range of medications including [l]{.smallcaps}-Dopa (all DLB patients), rivastigmine or donepezil (all AD and DLB patients with no differences in daily dosages between the 2 groups of patients), quetiapine (8 DLB and 6 AD), clozapine (4 DLB), and risperidone (4 AD) and clonazepam (the 14 DLB patients with RBD).

^1^H-MRS Findings {#s3b}
-----------------

Table [2](#BHU220TB2){ref-type="table"} summarizes ^1^H-MRS results. Figure [1](#BHU220F1){ref-type="fig"}*B* shows representative spectra for each group. [Supplementary Table 2](http://cercor.oxfordjournals.org/lookup/suppl/doi:10.1093/cercor/bhu220/-/DC1) shows the effects among groups from MANCOVA and MANOVA analyses. Lower NAA/tCr and higher tCho/tCr values were bilaterally observed in the thalami of DLB patients respect to controls. No changes were found in the thalami of AD patients compared with controls. The comparison between DLB and AD demonstrated tCho/tCr increase in the right thalamus of DLB patients. No tCr changes were found among groups. Assuming as nuisance factors age, MMSE, NPI hallucinations, UPDRS scores, on linear regression a significant relationship between tCho/tCr and CAF values within right thalamus (*R* = 0.86, *t* = 5.391, *P* \< 0.001) (Fig. [1](#BHU220F1){ref-type="fig"}*C*) was observed. Table 2Neurochemical changes in the thalami assessed by ^1^H-MRSMetabolitesThalamusControlsADDLBAD versus controls^a^DLB versus controls^a^AD versus DLB^a^NAA/tCrRight1.84 ± 0.121.73 ± 0.151.65 ± 0.2*P* = 0.160*P* **= 0.008***P* = 0.363Left1.82 ± 0.151.78 ± 0.191.68 ± 0.14*P* = 0.738*P* **= 0.045***P* = 0.173tCho/tCrRight0.72 ± 0.040.72 ± 0.070.8 ± 0.09*P* = 0.996*P* **= 0.014***P* **= 0.011**Left0.72 ± 0.050.76 ± 0.080.8 ± 0.11*P* = 0.315*P* **= 0.034***P* = 0.465tCr/water^b^Right5.2 ± 0.25.1 ± 0.44.9 ± 0.9*P* = 0.958*P* = 0.414*P* = 0.546Left5.2 ± 0.65.0 ± 0.75.0 ± 0.7*P* = 0.733*P* = 0.774*P* = 0.997[^11][^12][^13]

Thalamocortical Structural Connectivity {#s3c}
---------------------------------------

Figure [2](#BHU220F2){ref-type="fig"}*B* shows the thalamic connectivity-defined subregions projecting to: prefrontal cortex including the ventro-anterior and dorso-medial parts of the thalami;sensorimotor cortex including the ventrolateral part of the thalami;parieto-occipital cortex including the ventro-posterior part of the thalami and the superior portion of pulvinar;temporal cortex including the dorso-anterior part of the thalami and the inferior portion of pulvinar.Figure [2](#BHU220F2){ref-type="fig"}*D* shows the maps of connection probability of each thalamic subregion to specific cortical regions, for each group. When comparisons between groups were performed, no significant differences were observed on connection probability. As verified by visual inspection of "find the biggest" outputs, the location of each connectivity-defined thalamic region showed good correspondence among groups and it was in agreement with Oxford Thalamic Connectivity Atlas (Fig. [2](#BHU220F2){ref-type="fig"}*C*). Furthermore, the volumes of each thalamic region defined by "find the biggest" were not different among groups (see [Supplementary Table 3](http://cercor.oxfordjournals.org/lookup/suppl/doi:10.1093/cercor/bhu220/-/DC1)). Hence, the anatomy for each thalamic connectivity-defined region did not significantly change in pathological conditions with respect to controls.

Mean Diffusivity Changes Within Thalamic Regions {#s4}
================================================

Table [3](#BHU220TB3){ref-type="table"} shows grand mean MD values for each connectivity-defined subregion obtained from tractography-based subdivision of thalami. [Supplementary Table 4](http://cercor.oxfordjournals.org/lookup/suppl/doi:10.1093/cercor/bhu220/-/DC1) shows the effects among groups from MANCOVA and MANOVA analyses. [Supplementary Table 5](http://cercor.oxfordjournals.org/lookup/suppl/doi:10.1093/cercor/bhu220/-/DC1) shows grand mean MD values for each connectivity-defined subregion obtained from Oxford thalamic connectivity atlas. No differences were found between MD values obtained with probabilistic parcellation and MD values obtained with Oxford Thalamic Connectivity Atlas (see [Supplementary Table 6](http://cercor.oxfordjournals.org/lookup/suppl/doi:10.1093/cercor/bhu220/-/DC1)). Table 3Mean diffusivity values in each "connectivity-defined region" obtained from tractography-based parcellation of thalamiConnectivity-defined regionMean diffusivity (MD)Statistical comparison^a^TargetThalamusControlsADDLBAD versus controlsDLB versus controlsAD versus DLBPrefrontal cortexRight752 ± 15785 ± 67809 ± 52*P* = 0.211*P* **= 0.014***P* = 0.395Left752 ± 16784 ± 72815 ± 52*P* = 0.257*P* **= 0.008***P* = 0.243Sensorimotor cortexRight750 ± 19757 ± 71797 ± 60*P* = 0.933*P* = 0.079*P* = 0.131Left750 ± 37760 ± 80801 ± 47*P* = 0.876*P* = 0.061*P* = 0.136Parieto-occipital cortexRight759 ± 24793 ± 88843 ± 61*P* = 0.365*P* **= 0.004***P* = 0.085Left759 ± 28798 ± 93837 ± 59*P* = 0.289*P* **= 0.010***P* = 0.234Temporal cortexRight779 ± 20828 ± 70818 ± 52*P* **= 0.046***P* = 0.134*P* = 0.856Left782 ± 24830 ± 59818 ± 47*P* **= 0.024***P* = 0.111*P* = 0.757[^14][^15][^16]

In comparison to controls, DLB patients showed bilateral increases in MD in the connectivity-defined subregions projecting to the prefrontal and parieto-occipital cortices. As compared with controls, AD patients showed increase of MD in left connectivity-defined subregion projecting to the temporal cortex. No significant differences were found in the comparison between DLB and AD. Within the DLB group MD increases were not correlated with our primary measure of flCog (CAF score) or other clinical variables (e.g. FAB).

Discussion {#s5}
==========

In the current study, we demonstrated that DLB patients with flCog were affected by neurochemical imbalance in the thalami and by microstructural changes in the connectivity-defined regions projecting from thalamus to the frontal and parieto-occipital cortices.

Specifically, we found reduced NAA/tCr and increased tCho/tCr in the thalami of DLB with flCog.

TCr is a neuronal marker of energetic metabolism. Because its levels are typically stable in dementias ([@BHU220C30]), tCr has been used as internal reference in ^1^H-MRS studies on DLB ([@BHU220C46]; [@BHU220C31]; [@BHU220C25]). Consistent with this, our results showed that tCr was effectively unchanged in our groups, and thus suggest that the thalamic neurochemical alterations observed in our DLB patients are mainly attributable to NAA and tCho.

NAA is primarily located in neuron bodies, axons, and dendrites and it is a sensitive marker for neuronal density or viability ([@BHU220C30]). Therefore, NAA reduction suggested that DLB pathology could be associated to neurodegenerative processes in the thalami. Notably, this finding is consistent with a recent DTI study describing thalamic white matter disruption in DLB patients ([@BHU220C72]).

TCho provides a marker of the contribution of cytosolic glycerolphosphocholine and phosphocholine which are the products of membrane phosphatidyl choline breakdown and the precursors of choline and acetylcholine synthesis, respectively ([@BHU220C35]). It was hypothesized that higher tCho levels in DLB could be linked to the increase of membrane turnover due to dying of the neuropil and to down-regulation of choline acetyltransferase activity that it is reduced more severely in DLB with respect to AD ([@BHU220C75]; [@BHU220C42]; [@BHU220C65]; [@BHU220C30]). In this context, recent ^1^H-MRS studies have suggested that the increase in tCho could be a characteristic feature of DLB and independent from AD pathology ([@BHU220C30]; [@BHU220C25]). Furthermore, consistently with our findings on thalami, [@BHU220C37] observed thalamic cholinergic denervation in DLB but not in AD, suggesting a relationship between neurodegenerative involvement of thalamic cholinergic afferent projections and cognitive alteration in DLB.

TCho/tCr values in the thalamus were closely correlated with the presence and severity of flCog as assessed by CAF questionnaire. The cholinergic system is particularly implicated in attention and awareness ([@BHU220C54]; [@BHU220C36]). Studies on DLB patients reported attentional performance improvement following the cholinesterase inhibitors treatment ([@BHU220C73]). Furthermore, imaging studies observed cholinergic alterations related to flCog in the thalami of DLB patients ([@BHU220C53]; [@BHU220C49]; [@BHU220C56]). Thus, this strongly favors the role of cholinergic imbalance within thalami in the etiology of flCog in DLB.

In agreement with previous functional and structural studies by our groups ([@BHU220C24], [@BHU220C23]; [@BHU220C16]), we also observed predominant right lateralization of neurochemical alterations in DLB. These findings could be linked to the dominant role of the right hemisphere in attention ([@BHU220C64]). Further studies integrating structural and functional MRI techniques could clarify whether predominant right hemispheric dysfunction is truly a specific feature of DLB.

We observed that structural thalamocortical connectivity was affected in DLB patients with flCog. In this context, MD was specifically assessed because it is an index for both grey and white matters damage and its high values are associated to reduction in membrane density and cell loss of both neurons and glia ([@BHU220C8]).

Thalamic neurons regulate the cortico-cortical control acting as neuronal hub to synchronize oscillations between cortical areas ([@BHU220C59]). The modulation of thalamic activity can shift cortical activity by desynchronizing activated states (depolarized tonic firing mode) associated with arousal and/or by synchronizing deactivated states (burst firing mode) indicative of drowsiness ([@BHU220C40]; [@BHU220C27]). In this context, impaired thalamic activity has been associated with decreased levels of arousal ([@BHU220C69]; [@BHU220C21]).

We found that MD was bilaterally increased in the connectivity-defined subregion projecting from thalamus to frontal cortex in DLB as compared with controls. The thalamic nuclei serving prefrontal cortex play a relevant role in consciousness ([@BHU220C22]; [@BHU220C71]) and alertness ([@BHU220C66]). In particular, deficits in concentration can be observed when thalamic region projecting to prefrontal cortical network is damaged ([@BHU220C68]). Moreover, in agreement with our findings, a recent study showed that functional connectivity within thalamic region projecting to frontal lobe was altered in DLB patients with respect to controls ([@BHU220C34]). However, we did not observe a significant relationship between MD and CAF or FAB scores. However, in some respects this is not unexpected as across different neuroimaging modalities there has been an emphasis on symptom in DLB being more reliant upon posterior cortical function ([@BHU220C28]; [@BHU220C41]; [@BHU220C51]; [@BHU220C33]; Taylor et al. 2012; [@BHU220C16]). Indeed, in support of this we found that MD was bilaterally increased in the connectivity-defined subregion projecting from thalamus to parieto-occipital cortex in DLB as compared with controls although again there was no relationship between MD and CAF for these projections. Therefore, while the integrity of thalamocortical projections may be disrupted in DLB, this may be less relevant to the pathophysiology of flCog; the ^1^H-MRS findings noted above support an argument that intrinsic neurochemical changes in the thalamus are more important, at least for flCog.

The ventrolateral region of thalamus and anterior portion of pulvinar synchronize the activity across posterior cortical regions, filtering distracters ([@BHU220C20]) and regulating visuospatial attention ([@BHU220C57]). Particularly, pulvinar is ideally situated to integrate bottom-up orienting, driven either by sensory and subcortical inputs, with top-down orienting, driven by goals and context ([@BHU220C71]). Notably, it was observed close relationship between pulvinar lesion and visuo-attentional deficits ([@BHU220C2]). On these bases, we propose that the deregulation of parieto-occipito-thalamic connectivity could be related to alteration in visual attention and visual dysfunction characterizing DLB patients.

Furthermore, we observed that AD patients were affected by bilateral microstructural damage in the connectivity-defined subregion projecting from thalamus to temporal cortex. As assessed by structural connectivity analysis, this connectivity-defined subregion included the antero-ventral nuclei of thalamus and the posterior pulvinar nuclei, which are directly connected to hippocampus via the fornix and via the temporo-pulvinar tract. The integrity of these connections is essential for episodic memory ([@BHU220C1]), which is specifically affected in AD ([@BHU220C17]). In this context, [@BHU220C76] reported that AD patients were affected by structural alteration of the antero-dorsal thalamic nuclei. Therefore, we suggest that the microstructural alteration of connectivity-defined subregion projecting from thalamus to temporal cortex could be linked to great memory impairment affecting AD patients.

In conclusion, our findings highlight the critical role of thalamus in DLB pathology. By multimodal techniques including structural MRI, DTI, and ^1^H-MRS, we have shown, firstly, microstructural damage in thalamic regions related to alertness and attention and, secondly, metabolic alterations related to neuronal damage and cholinergic dysfunction in the thalami. Furthermore, our results suggest that cholinergic imbalance within thalami is closely linked to frequency and duration of flCog occurring in DLB.

A possible limitation of our study is that we focused our analyses on DLB patients with flCog. Therefore our conclusions may be less applicable to DLB without flCog. However, we underline that in the present study a CAF score ≥2 was considered sufficient to define a patient as affected by flCog ([@BHU220C6]), at difference with the study in which this scale was originally proposed, where a higher cut-off of 5 at the CAF questionnaire was shown to have high sensitivity and specificity to DLB.
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[^1]: Note: Values are expressed as mean ± standard deviation.

[^2]: ^a^The *P*-values were calculated using the one-way ANOVA; Tukey'\'s HSD post hoc test was also performed when *F*-test was significant.

[^3]: ^b^Main interaction among groups: *F*~2,44~ = 0.003, *P* = 0.997.

[^4]: ^c^The *P*-values were calculated using *χ*² test: *χ*²~1~ = 0.022, *P* = 0.881.

[^5]: ^d^The *P*-values were calculated using the independent-samples *t*-test: *t*~30~ = −0.522, *P* = 0.605.

[^6]: ^e^Main interaction among groups: *F*~2,44~ = 0.846, *P* = 0.436.

[^7]: ^f^The *P*-values were calculated using the independent-samples *t*-test: *t*~30~ = −0.275; *P* = 0.786.

[^8]: ^g^Main interaction among groups: *F*~2,44~ = 34.223, *P* \< 0.001; post hoc: controls versus AD, *P* \< 0.001; controls versus DLB, *P* \< 0.001 and AD versus DLB, *P* = 0.982.

[^9]: ^h^Main interaction among groups: *F*~2,44~ = 45.367, *P* \< 0.001; post hoc: controls versus AD, *P* \< 0.001; controls versus DLB, *P* \< 0.001 and AD versus DLB, *P* = 0.998.

[^10]: ^i^Main interaction among groups: *F*~2,44~ = 74.363, *P* \< 0.001; post hoc: controls versus AD, *P* \< 0.001; controls versus DLB, *P* \< 0.001 and AD versus DLB, *P* = 0.987.

[^11]: AD, Alzheimer\'s disease; DLB, dementia with Lewy bodies; NAA, *N*-acetyl-aspartate; tCr, total creatine; tCho, total choline.

[^12]: ^a^Tukey\'s HSD post hoc test was performed for assessing pair-wise differences between groups.

[^13]: ^b^Value × 10^−4^. Bold characters indicate statistically significant results. Significant mean differences were found among groups by MANOVA (*F*~12,74~ = 3.216, *P* = 0.001).

[^14]: Note: MD values (×10^−4^mm^2^/s) are expressed as mean ± standard deviation. Bold characters indicate statistically significant results. Significant mean differences were found among groups by MANOVA (*F*~16,70~ = 3.124, *P* = 0.001).

[^15]: ^a^*P-*values from Tukey\'s HSD post hoc.

[^16]: AD, Alzheimer\'s disease; DLB, dementia with Lewy bodies.
